Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

2.

Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform.

Aleksandrova K, Leise J, Priesner C, Melk A, Kubaink F, Abken H, Hombach A, Aktas M, Essl M, Bürger I, Kaiser A, Rauser G, Jurk M, Goudeva L, Glienke W, Arseniev L, Esser R, Köhl U.

Transfus Med Hemother. 2019 Feb;46(1):47-54. doi: 10.1159/000495772. Epub 2019 Feb 4. Review.

3.

Cellular Therapeutics - Living Drugs: A Rising Star at the Horizon of Immunotherapy in Hematology and Oncology.

Humpe A, Köhl U.

Transfus Med Hemother. 2019 Feb;46(1):2. doi: 10.1159/000497051. Epub 2019 Feb 4. No abstract available.

4.

Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation.

Bitar M, Boldt A, Freitag MT, Gruhn B, Köhl U, Sack U.

Front Immunol. 2019 Apr 5;10:722. doi: 10.3389/fimmu.2019.00722. eCollection 2019.

5.

Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1G93A mouse model of amyotrophic lateral sclerosis.

Bursch F, Rath KJ, Sarikidi A, Böselt S, Kefalakes E, Osmanovic A, Thau-Habermann N, Klöß S, Köhl U, Petri S.

J Tissue Eng Regen Med. 2019 Apr;13(4):649-663. doi: 10.1002/term.2846. Epub 2019 Mar 20.

PMID:
30811816
6.

[What is established in cell therapies? : Possibilities and limits in immuno-oncology].

Quaiser A, Köhl U.

Internist (Berl). 2018 Dec;59(12):1230-1238. doi: 10.1007/s00108-018-0516-0. Review. German.

PMID:
30367191
7.

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.

Kloess S, Ede Valverde da Silva A, Oberschmidt O, Gardlowski T, Matthies N, Vyas M, Arseniev L, Heuser M, Pogge von Strandmann E, Köhl U.

Front Immunol. 2018 Oct 8;9:2326. doi: 10.3389/fimmu.2018.02326. eCollection 2018.

8.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. doi: 10.1016/j.bbmt.2018.07.015. Epub 2018 Jul 20.

9.

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.

Köhl U, Arsenieva S, Holzinger A, Abken H.

Hum Gene Ther. 2018 May;29(5):559-568. doi: 10.1089/hum.2017.254. Epub 2018 Apr 5.

PMID:
29620951
10.

Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.

Kloess S, Ede Valverde da Silva A, Oberschmidt O, Gardlowski T, Matthies N, Vyas M, Arseniev L, Heuser M, Pogge von Strandmann E, Köhl U.

Front Immunol. 2017 Sep 8;8:1100. doi: 10.3389/fimmu.2017.01100. eCollection 2017. Erratum in: Front Immunol. 2018 Oct 08;9:2326.

11.

Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E.

Front Immunol. 2017 Apr 26;8:458. doi: 10.3389/fimmu.2017.00458. eCollection 2017. Review.

12.

Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E.

Oncoimmunology. 2016 Jul 15;5(9):e1211220. eCollection 2016.

13.

Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms.

Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhoff B, Heuft HG, Goudeva L, Blasczyk R, Arseniev L, Köhl U, Eiz-Vesper B, Klöß S.

Front Immunol. 2016 Sep 30;7:393. eCollection 2016.

14.

Biohybrid cochlear implants in human neurosensory restoration.

Roemer A, Köhl U, Majdani O, Klöß S, Falk C, Haumann S, Lenarz T, Kral A, Warnecke A.

Stem Cell Res Ther. 2016 Oct 7;7(1):148.

15.

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.

Klöss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, Pogge von Strandmann E, Morgan MA, Arseniev L, Seitz O, Köhl U.

Front Immunol. 2015 Nov 2;6:543. doi: 10.3389/fimmu.2015.00543. eCollection 2015.

16.

Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.

Klöß S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, Glienke W, Seitz O, Köhl U.

Oncoimmunology. 2015 May 29;4(11):e1055993. eCollection 2015 Nov.

17.

Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation.

Elze MC, Ciocarlie O, Heinze A, Kloess S, Gardlowski T, Esser R, Klingebiel T, Bader P, Huenecke S, Serban M, Köhl U, Hutton JL.

Bone Marrow Transplant. 2015 Feb;50(2):266-73. doi: 10.1038/bmt.2014.257. Epub 2014 Nov 10.

PMID:
25387093
18.

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.

Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.

19.

Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.

Bunse CE, Borchers S, Varanasi PR, Tischer S, Figueiredo C, Immenschuh S, Kalinke U, Köhl U, Goudeva L, Maecker-Kolhoff B, Ganser A, Blasczyk R, Weissinger EM, Eiz-Vesper B.

PLoS One. 2013 Dec 4;8(12):e77925. doi: 10.1371/journal.pone.0077925. eCollection 2013.

20.

Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations.

Ungerer C, Quade-Lyssy P, Radeke HH, Henschler R, Königs C, Köhl U, Seifried E, Schüttrumpf J.

Stem Cells Dev. 2014 Apr 1;23(7):755-66. doi: 10.1089/scd.2013.0335. Epub 2013 Nov 13.

21.

Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.

Kuçi Z, Seiberth J, Latifi-Pupovci H, Wehner S, Stein S, Grez M, Bönig H, Köhl U, Klingebiel T, Bader P, Kuçi S.

Haematologica. 2013 Oct;98(10):1609-16. doi: 10.3324/haematol.2013.092700. Epub 2013 Aug 23.

22.

A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.

Eißmann M, Schwamb B, Melzer IM, Moser J, Siele D, Köhl U, Rieker RJ, Wachter DL, Agaimy A, Herpel E, Baumgarten P, Mittelbronn M, Rakel S, Kögel D, Böhm S, Gutschner T, Diederichs S, Zörnig M.

PLoS One. 2013 May 22;8(5):e64873. doi: 10.1371/journal.pone.0064873. Print 2013.

23.

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, von Strandmann EP.

Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5.

24.

Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells.

Pajtler KW, Rebmann V, Lindemann M, Schulte JH, Schulte S, Stauder M, Leuschner I, Schmid KW, Köhl U, Schramm A, Eggert A.

Int J Cancer. 2013 Aug 15;133(4):908-19. doi: 10.1002/ijc.28096. Epub 2013 Mar 16.

25.

Pediatric apheresis with a novel apheresis device with electronic interface control.

Sörensen J, Jarisch A, Smorta C, Köhl U, Bader P, Seifried E, Bönig H.

Transfusion. 2013 Apr;53(4):761-5. doi: 10.1111/j.1537-2995.2012.03823.x. Epub 2012 Aug 6.

PMID:
22882156
26.

[Immunotherapy with allogeneic NK cells after stem cell transplantation: harnessing a potent "killer" of tumor cells].

Klöß S, Köhl U.

Pharm Unserer Zeit. 2012 May;41(3):239-45. Review. German. No abstract available.

PMID:
22844672
27.

Regulation of HIV-1 infection in cells derived from purified CD34+ cells through manipulation of APOBEC3G expression.

Heinzelmann A, Stein S, Köhl U, Dietrich U, von Briesen H.

Curr HIV Res. 2010 Oct;8(7):554-63.

PMID:
20642434
28.

TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes.

Lindner SC, Köhl U, Maier TJ, Steinhilber D, Sorg BL.

J Leukoc Biol. 2009 Aug;86(2):389-99. doi: 10.1189/jlb.1008591. Epub 2009 Apr 28.

PMID:
19401382
29.

Infections and vesicoureteral reflux.

Weingärtner K, Köhl U, Riedmiller H.

Curr Opin Urol. 1998 Nov;8(6):505-10.

PMID:
17039067
30.

Primary intestinal aspergillosis after high-dose chemotherapy and autologous stem cell rescue.

Lehrnbecher T, Becker M, Schwabe D, Köhl U, Kriener S, Hunfeld KP, Schmidt H, Beyer P, Klingebiel T, Bader P, Sörensen J.

Pediatr Infect Dis J. 2006 May;25(5):465-6.

PMID:
16645519
31.

Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children.

Lang P, Pfeiffer M, Handgretinger R, Schumm M, Demirdelen B, Stanojevic S, Klingebiel T, Köhl U, Kuci S, Niethammer D.

Bone Marrow Transplant. 2002 Mar;29(6):497-502.

32.

Ten years' experience with the submucosally embedded in situ appendix in continent cutaneous diversion.

Gerharz EW, Köhl UN, Melekos MD, Bonfig R, Weingärtner K, Riedmiller H.

Eur Urol. 2001 Dec;40(6):625-31.

PMID:
11805408
33.

[Adrenalectomy within the scope of tumor nephrectomy--overtreatment?].

Kiesow U, Kieser W, Köhl U, Weingärtner K, Riedmiller H.

Urologe A. 2001 Jan;40(1):52-7. Review. German.

PMID:
11225433
34.

Continent urinary diversion in preparation for renal transplantation: a staged approach.

Riedmiller H, Gerharz EW, Köhl U, Weingärtner K.

Transplantation. 2000 Dec 27;70(12):1713-7.

PMID:
11152102
35.

Involvement of the urogenital tract in patients with five or more separate malignant neoplasms.

Melekos MD, Gerharz EW, Weingärtner K, Köhl U, Riedmiller H.

Eur Urol. 1999 Dec;36(6):650-1. No abstract available.

PMID:
10559622
36.

Radical cystoprostatectomy combined with Mainz pouch bladder substitution to the urethra: long-term results.

Leissner J, Stein R, Hohenfellner R, Köhl U, Riedmiller H, Schröder A, Lampel A, Thüroff JW.

BJU Int. 1999 Jun;83(9):964-70.

PMID:
10368237
37.

Experience with the Mainz modification of ureterosigmoidostomy.

Gerharz EW, Köhl UN, Weingärtner K, Kleinhans BJ, Melekos MD, Riedmiller H.

Br J Surg. 1998 Nov;85(11):1512-6.

PMID:
9823913
38.

Complications related to different continence mechanisms in ileocecal reservoirs.

Gerharz EW, Köhl U, Weingärtner K, Melekos MD, Bonfig R, Riedmiller H.

J Urol. 1997 Nov;158(5):1709-13.

PMID:
9334584
39.

Quality of life after cystectomy and urinary diversion: results of a retrospective interdisciplinary study.

Gerharz EW, Weingärtner K, Dopatka T, Köhl UN, Basler HD, Riedmiller HN.

J Urol. 1997 Sep;158(3 Pt 1):778-85. Erratum in: J Urol 1997 Dec;158(6):2253.

PMID:
9258080
40.
41.

A simple device in the prevention of recurrent appendico-umbilical stenosis.

Köhl U, Gerharz EW, Weingärtner K, Riedmiller H.

Br J Urol. 1996 Apr;77(4):603-4. No abstract available.

PMID:
8777629
42.

Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity.

Köhl U, Schwabe D, Montag E, Bauer S, Mieth B, Cinatl J, Cinatl J Jr, Rohrbach E, Mainke M, Weissflog A, et al.

Eur J Cancer. 1995;31A(2):209-14.

PMID:
7718327
43.

Multiple (five) synchronous primary malignant neoplasms of dissimilar histogenesis including a malignant fibrous histiocytoma of the bladder.

Weingärtner K, Melekos MD, Gerharz EW, Köhl U, Neumann K, Riedmiller H.

Int Urol Nephrol. 1995;27(2):157-66.

PMID:
7591572
44.

Haemorrhagic infarction of a prolapsed orthotopic ureterocele causing upper urinary tract obstruction.

Gerharz EW, Weingärtner K, Köhl U, Riedmiller H.

Br J Urol. 1994 Nov;74(5):670-1. No abstract available.

PMID:
7827823
45.

[Focal necrotising vasculitis of the testis. Testicular manifestations of immunologic diseases in differential diagnosis of testicular cancer].

Weingärtner K, Gerharz EW, Köhl U, Bittinger A, Schwerk WB, Riedmiller H.

Urologe A. 1994 Jul;33(4):320-4. Review. German.

PMID:
7941180
46.
47.

Determination of m-iodobenzylguanidine in serum and urine by high-performance liquid chromatography.

Schwabe D, Rohrbach E, Köhl U.

J Chromatogr. 1989 Jan 27;487(1):177-82. No abstract available.

PMID:
2715263
48.

Management of clinical data in urology. Experience with integrated personal computers and a relational database.

Engelmann U, von Wallenberg H, Köhl U, Geesken E.

Br J Urol. 1988 Jun;61(6):527-30.

PMID:
3401663
49.

Murine Fc gamma receptor proteins: identification of a previously unrecognized molecule with a monoclonal antibody (12-15).

Altevogt P, Heckl-Oestreicher G, Lang E, Kohl U, Kratzin H, Schirrmacher V.

Eur J Immunol. 1988 May;18(5):677-83.

PMID:
2967758
50.

Structural basis for altered soybean agglutinin lectin binding between a murine metastatic lymphoma and an adhesive low malignant variant.

Lang E, Kohl U, Schirrmacher V, Brossmer R, Altevogt P.

Exp Cell Res. 1987 Nov;173(1):232-43.

PMID:
2445594

Supplemental Content

Support Center